Literature DB >> 2170694

Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.

N D Christensen1, J W Kreider, N M Cladel, S D Patrick, P A Welsh.   

Abstract

Monoclonal antibodies recognizing human papillomavirus type 11 (HPV-11) were prepared from BALB/c mice immunized with intact HPV-11 virions obtained from morphologically transformed human foreskin xenografts grown subrenally in athymic mice. Four of five monoclonal antibodies that were reactive by enzyme-linked immunosorbent assay only to intact virions neutralized HPV-11 infectivity in the athymic mouse xenograft system.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2170694      PMCID： PMC248629          DOI： 10.1128/JVI.64.11.5678-5681.1990

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  21 in total

1.  STUDIES ON THE MECHANISM RESPONSIBLE FOR THE SPONTANEOUS REGRESSION OF THE SHOPE RABBIT PAPILLOMA.

Authors:  J W KREIDER
Journal:  Cancer Res       Date:  1963-10       Impact factor: 12.701

2.  Structural polypeptides of rabbit, bovine, and human papillomaviruses.

Authors:  M Favre
Journal:  J Virol       Date:  1975-05       Impact factor: 5.103

3.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

4.  Production of a monoclonal antibody against an epitope on HeLa cells that is the functional poliovirus binding site.

Authors:  P Nobis; R Zibirre; G Meyer; J Kühne; G Warnecke; G Koch
Journal:  J Gen Virol       Date:  1985-12       Impact factor: 3.891

5.  Topographical and conformational epitopes of bovine papillomavirus type 1 defined by monoclonal antibodies.

Authors:  L M Cowsert; P Lake; A B Jenson
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

6.  A quantitative in vitro focus assay for bovine papilloma virus.

Authors:  I Dvoretzky; R Shober; S K Chattopadhyay; D R Lowy
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

7.  Susceptibility of various human tissues to transformation in vivo with human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; M H Stoler; R J Zaino; P Welsh
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

8.  Laboratory production in vivo of infectious human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; A E Leure-Dupree; R J Zaino; J A Weber
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

9.  Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence.

Authors:  S Kennedy-Stoskopf; O Narayan
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

10.  Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata.

Authors:  J W Kreider; M K Howett; S A Wolfe; G L Bartlett; R J Zaino; T Sedlacek; R Mortel
Journal:  Nature       Date:  1985 Oct 17-23       Impact factor: 49.962
View more
  40 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells.

Authors:  Timothy D Culp; Lynn R Budgeon; M Peter Marinkovich; Guerrino Meneguzzi; Neil D Christensen
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

Review 5.  Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.

Authors:  Christine Roberts; Tina Green; Erica Hess; Katie Matys; Martha J Brown; Richard M Haupt; Alain Luxembourg; Scott Vuocolo; Alfred Saah; Joseph Antonello
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.

Authors:  Y L Lin; L A Borenstein; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus.

Authors:  P Le Cann; A Touze; N Enogat; D Leboulleux; C Mougin; M C Legrand; C Calvet; J M Afoutou; P Coursaget
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

8.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58.

Authors:  Martha J Brown; Hanna Seitz; Victoria Towne; Martin Müller; Adam C Finnefrock
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

10.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.